Abstracts tagged "IL6"

Abstract Number: 1247 • ACR Convergence 2021
Plasma Cell-free DNA Is a Useful Biomarker for Tocilizumab Therapy in Rheumatoid Arthritis
Teppei Hashimoto¹, Yuichi Yokoyama², Takahiro Yoshikawa³, Tetsuya Furukawa⁴, Naoto Azuma⁵, Akira Hashiramoto⁶ and Kiyoshi Matsui⁷, ¹Hyogo College of Medicine, Kobe, Hyogo, Japan, ²Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, ³Hyogo College of Medicine, Nishinomiya, Japan, ⁴Hyogo college of Medicine, Nishinomiya, Hyogo, Japan, ⁵Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan, ⁶Kobe University, Kobe, Japan, ⁷Hyogo College of Medicine, Nishinomiya-city, Hyogo, Japan
Background/Purpose: Endogenous DNA derived from nuclei is released into the blood circulation as cell-free DNA (cfDNA) following cell damage or death. cfDNA is associated with…
Abstract Number: 2397 • 2019 ACR/ARP Annual Meeting
Skin Lesions as a Side Effect of anti-IL6 Therapy: Transcriptome Analysis of Peripheral Blood Shows a Risk of Paradoxical Neutrophil Activation and Exacerbation of Skin Ulcer
Yoshinobu Koyama¹, Akemi Senoo ², Kaho Otsuki ³, Yoshiharu Sato ⁴, Mari Yamaguchi ² and Toshie Higuchi ¹, ¹Center for Autoimmune Diseases, Division of Rheumatology, Japanese Red Cross Okayama Hospital, Okayama, Japan, ²Division of Dermatology, Japanese Red Cross Okayama Hospital, Okayama, Japan, ³Center for Autoimmune Diseases, Division of Rheumatology, Okayama, Japan, ⁴DNA Chip Research Inc, Tokyo, Japan
Background/Purpose: Skin lesion as a side effect of Tocilizumab (TCZ) has not been paid much attention. In the drug information sheets, incidence of dermatological adverse…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].